BUZZ-路透报道Hims推出仿制Wegovy药片后，诺和诺德下跌

路透中文

Feb 05

BUZZ-路透报道Hims推出仿制Wegovy药片后，<a href="https://laohu8.com/S/NVO">诺和诺德</a>下跌

2月5日 - ** 丹麦制药商诺和诺德NOVOb.CO股价下跌，因为路透报道称，Hims and Hers HealthHIMS.N正在以每月49美元的介绍性价格推出诺和诺德Wegovy药片的仿制药 (link)。

** 诺和诺德在丹麦上市的股票下跌10%，报收于274丹麦克朗；美股NVO.N在盘前交易中下跌6.5%。

** Hims表示，其复方药丸使用与Wegovy相同的活性成分--semaglutide，首次付款后的月费为99美元，而诺和诺德的月费为199美元。

** Hims and Hers 公司的股价在盘前大涨 13%。

** 诺和诺德去年结束了与 Hims 的合作，并对复方Wegovy仿制药的安全性和市场营销提出了担忧。

** 本周早些时候，诺和诺德预测 (link) 2026 年的销售额下降幅度将超过预期，这凸显了减肥药市场竞争的加剧。

** 2025 年诺和诺德股价下跌约 42%。

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609134306"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609134306\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609134306?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-02-05 22:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609134306","market":"hk","top_or_hot":-1,"title":"BUZZ-路透报道Hims推出仿制Wegovy药片后，诺和诺德下跌","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-路透报道Hims推出仿制Wegovy药片后，<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>下跌</title></head><body><p>\n<span>2月5日</span><span> - </span>** 丹麦制药商诺和诺德<span>NOVOb.CO</span>股价下跌，因为路透报道称，Hims and Hers Health<span>HIMS.N</span>正在以每月49美元的介绍性价格推出诺和诺德Wegovy药片的仿制药 (<span>link</span>)。</p><p>** 诺和诺德在丹麦上市的股票下跌10%，报收于274丹麦克朗；美股<span>NVO.N</span>在盘前交易中下跌6.5%。</p><p>** Hims表示，其复方药丸使用与Wegovy相同的活性成分--semaglutide，首次付款后的月费为99美元，而诺和诺德的月费为199美元。</p><p>** Hims and Hers 公司的股价在盘前大涨 13%。</p><p>** 诺和诺德去年结束了与 Hims 的合作，并对复方Wegovy仿制药的安全性和市场营销提出了担忧。</p><p>** 本周早些时候，诺和诺德预测 (<span>link</span>) 2026 年的销售额下降幅度将超过预期，这凸显了减肥药市场竞争的加剧。</p><p>** 2025 年诺和诺德股价下跌约 42%。</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-路透报道Hims推出仿制Wegovy药片后，诺和诺德下跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-路透报道Hims推出仿制Wegovy药片后，诺和诺德下跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-02-05 22:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-路透报道Hims推出仿制Wegovy药片后，<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>下跌</title></head><body><p>\n<span>2月5日</span><span> - </span>** 丹麦制药商诺和诺德<span>NOVOb.CO</span>股价下跌，因为路透报道称，Hims and Hers Health<span>HIMS.N</span>正在以每月49美元的介绍性价格推出诺和诺德Wegovy药片的仿制药 (<span>link</span>)。</p><p>** 诺和诺德在丹麦上市的股票下跌10%，报收于274丹麦克朗；美股<span>NVO.N</span>在盘前交易中下跌6.5%。</p><p>** Hims表示，其复方药丸使用与Wegovy相同的活性成分--semaglutide，首次付款后的月费为99美元，而诺和诺德的月费为199美元。</p><p>** Hims and Hers 公司的股价在盘前大涨 13%。</p><p>** 诺和诺德去年结束了与 Hims 的合作，并对复方Wegovy仿制药的安全性和市场营销提出了担忧。</p><p>** 本周早些时候，诺和诺德预测 (<span>link</span>) 2026 年的销售额下降幅度将超过预期，这凸显了减肥药市场竞争的加剧。</p><p>** 2025 年诺和诺德股价下跌约 42%。</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKVL7J92.USD","symbol_name":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL4S3Z11LQ:1","article_id":"2609134306","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609134306","pubTimestamp":1770300547,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"2月5日 - ** 丹麦制药商诺和诺德NOVOb.CO股价下跌，因为路透报道称，Hims and Hers HealthHIMS.N正在以每月49美元的介绍性价格推出诺和诺德Wegovy药片的仿制药 。** Hims表示，其复方药丸使用与Wegovy相同的活性成分--semaglutide，首次付款后的月费为99美元，而诺和诺德的月费为199美元。** Hims and Hers 公司的股价在盘前大涨 13%。** 诺和诺德去年结束了与 Hims 的合作，并对复方Wegovy仿制药的安全性和市场营销提出了担忧。** 2025 年诺和诺德股价下跌约 42%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4532":"文艺复兴科技持仓","HIMS":"Hims & Hers Health Inc.","BK4599":"减肥药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4588":"碎股","BK4007":"制药","NVO":"诺和诺德","NVOX":"2倍做多NVO ETF-Defiance","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4196":"保健护理服务","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)"},"translate_title":"BUZZ-Novo Nordisk falls after Reuters reports Hims launches generic Wegovy tablets","themeId":"c1153e9c0a8e9571f0041cca121599eb","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1.9,"NVOH":0.6,"NVOX":0.6,"NVO":1.95},"content_text":"BUZZ-路透报道Hims推出仿制Wegovy药片后，诺和诺德下跌\n2月5日 - ** 丹麦制药商诺和诺德NOVOb.CO股价下跌，因为路透报道称，Hims and Hers HealthHIMS.N正在以每月49美元的介绍性价格推出诺和诺德Wegovy药片的仿制药 (link)。** 诺和诺德在丹麦上市的股票下跌10%，报收于274丹麦克朗；美股NVO.N在盘前交易中下跌6.5%。** Hims表示，其复方药丸使用与Wegovy相同的活性成分--semaglutide，首次付款后的月费为99美元，而诺和诺德的月费为199美元。** Hims and Hers 公司的股价在盘前大涨 13%。** 诺和诺德去年结束了与 Hims 的合作，并对复方Wegovy仿制药的安全性和市场营销提出了担忧。** 本周早些时候，诺和诺德预测 (link) 2026 年的销售额下降幅度将超过预期，这凸显了减肥药市场竞争的加剧。** 2025 年诺和诺德股价下跌约 42%。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}